Oncology
1 drug is in development for Carcinoma.
- Companies
- 1
- Clinical trials
- 11
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Carcinoma pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| Taletrectinib | Nuvation Bio Inc. (NUVB) |
About this indication
Carcinoma context
Oncology·MeSH: Carcinoma (D002277)
Also known as: Carcinomas, Epithelial Neoplasm, Malignant, Epithelial Tumor, Malignant, Epithelioma, Epitheliomas, Malignant Epithelial Neoplasms, Malignant Epithelial Tumors
Prevalence
14.0 / 100K
Incidence
6.0 / 100K/yr
Frequently asked questions
How many drugs are in development for Carcinoma?
BioSniper tracks 1 drug in development for Carcinoma across 1 company.
How many clinical trials target Carcinoma?
There are 11 clinical trials targeting Carcinoma tracked by BioSniper.
What is the prevalence of Carcinoma?
The estimated prevalence of Carcinoma is approximately 14.0 per 100,000 population.